MLH1 Peptide
€100.00
In stock
SKU
350529
Protein Family: Enzymes
Pathway and Disease: Cancers, Replication and Repair
Alternate Names: DNA mismatch repair protein Mlh1; MutL protein homolog 1; MLH1; COCA2
Accession No.: P40692
Description:
DNA mismatch repair protein Mlh1 (MLH1) is involved in the repair of DNA mismatches. MLH1 is part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2, Turcot syndrome, Muir-Torre syndrome, including brain, colorectal, breast and endometrial tumors.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1851 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200167 is selected from a sequence within the C-term region of human MLH1. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C80H123N25O24S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Replication and Repair
Alternate Names: DNA mismatch repair protein Mlh1; MutL protein homolog 1; MLH1; COCA2
Accession No.: P40692
Description:
DNA mismatch repair protein Mlh1 (MLH1) is involved in the repair of DNA mismatches. MLH1 is part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2, Turcot syndrome, Muir-Torre syndrome, including brain, colorectal, breast and endometrial tumors.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1851 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200167 is selected from a sequence within the C-term region of human MLH1. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C80H123N25O24S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review